Zydus Launches ANVIMO to Revolutionize CMV Prevention in Transplant Patients

Health Desk Zydus launched ANVIMO, an affordable alternative for CMV prevention in transplant patients, reducing costs by 91%. The drug ensures safer, effective treatment, improving access and transplant outcomes in India. Zydus Lifesciences has announced a breakthrough in preventing Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) and kidney transplant pati